{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:50:08Z","timestamp":1777992608068,"version":"3.51.4"},"reference-count":89,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Paediatric B\u2010cell non\u2010Hodgkin lymphoma (B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>) compromises a heterogeneous group of histological entities of which Burkitt lymphoma is the most common. In resource\u2010rich countries, the expected cure rate is in excess of 85% with application of risk\u2010adapted short intensive chemotherapy. In recent years, large paediatric cooperative group trials have sought to improve upon outcomes by decreasing the intensity of cytotoxic treatment as well as introducing targeted therapies, such as rituximab. These efforts have resulted in excellent outcomes, however there remains a group of high\u2010risk patients for whom novel treatment approaches are needed. In this review, we will summarize the recent paediatric clinical trials in B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> as well as compare treatment approaches across the major cooperative groups. We will also highlight our current understanding of the molecular biology of paediatric B\u2010<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> with a focus on how this may help guide future rational targeted therapy.<\/jats:p>","DOI":"10.1111\/bjh.13969","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T15:40:32Z","timestamp":1458574832000},"page":"531-544","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Recent molecular and therapeutic advances in B\u2010cell non\u2010Hodgkin lymphoma in children"],"prefix":"10.1111","volume":"173","author":[{"given":"Lisa","family":"Giulino\u2010Roth","sequence":"first","affiliation":[{"name":"Department of Pediatrics Weill Cornell Medical College New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanton","family":"Goldman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Medical City Children's Hospital and Texas Oncology Dallas TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3685"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02647.x"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302954"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12434"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3814"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.04.011"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633685"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05735.x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402402"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3369"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2004.01.008"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055759"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-349662"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood.V124.21.963.963","article-title":"Interim analysis of a phase 1 study of the antibody\u2010drug conjugate SGN\u2010CD19A in relapsed or refractory B\u2010lineage acute leukemia and highly aggressive lymphoma","volume":"124","author":"Fathi A.T.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4901"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12542"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07144.x"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422709"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437624"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24722"},{"key":"e_1_2_12_27_1","first-page":"4","article-title":"Reduced burden of chemotherapy in children, adolescents and young adults (CAYA) with French\u2010Amerian\u2010British Group B mature B\u2010cell lymphoma (FAB B\u2010MBCL)","volume":"171","author":"Goldman S.","year":"2015","journal-title":"British Journal of Haematology"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.255"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13040"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1182\/blood.V124.21.3703.3703","article-title":"Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed\/refractory B\u2010cell precursor acute lymphoblastic leukemia","volume":"124","author":"Gore L.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21753"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.09.021"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3545"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055351"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.1777.1777"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136465"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3413"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121343109"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200403000-00006"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2468"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-015-0466-9"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6791"},{"key":"e_1_2_12_48_1","first-page":"411","article-title":"The primary mediastinal clear cell lymphoma of B\u2010cell type has variable defects in MHC antigen expression","volume":"59","author":"Moller P.","year":"1986","journal-title":"Immunology"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.518"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10351"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9117"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"e_1_2_12_53_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V126.23.182.182","article-title":"A phase 1 study of denintuzumab mafodotin (SGN\u2010CD19A) in relapsed\/refactory B\u2010lineage non\u2010Hodgkin lymphoma","volume":"126","author":"Moskowitz C.H.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_2_12_55_1","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non\u2010Hodgkin's lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy S.B.","year":"1980","journal-title":"Seminars in Oncology"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.3159"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08772.x"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07967.x"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5714"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4213"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.892"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3370"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.312"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.06988.x"},{"key":"e_1_2_12_67_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V126.23.473.473","article-title":"Phase 1 study of tazemetostat (EPZ\u20106438), an inhibitor of enhancer of zeste\u2010homolog 2 (EZH2): preliminary safety and activity in relapsed or refractory non\u2010Hodgkin lymphoma (NHL) patients","volume":"126","author":"Ribrag V.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2469"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq418"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031074"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7203"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1636"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.06.012"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605093341906"},{"key":"e_1_2_12_76_1","first-page":"8515","article-title":"Phase I trial of 19\u201028z chimeric antigen receptor modified T cells (19\u201028z CAR\u2010T) post\u2010high dose therapy and autologous stem cell transplant (HDT\u2010ASCT) for relapsed and refractory (rel\/ref) aggressive B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL)","volume":"33","author":"Sauter C.S.","year":"2015","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11378"},{"key":"e_1_2_12_78_1","first-page":"8516","article-title":"Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"33","author":"Schuster S.J.","year":"2015","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08681.x"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13443"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2813"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-326538"},{"key":"e_1_2_12_83_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_12_84_1","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1182\/blood.V124.21.4460.4460","article-title":"Treatment of relapsed\/refractory diffuse large B\u2010cell lymphoma with the bispecific T\u2010cell engager (BiTE\u00ae) antibody construct blinatumomab: primary analysis results from an open\u2010label, phase 2 study","volume":"124","author":"Viardot A.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3601"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1732008100"}],"updated-by":[{"DOI":"10.1111\/bjh.14409","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:00:00Z","timestamp":1477440000000}}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13969","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T14:05:11Z","timestamp":1694527511000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,21]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/bjh.13969"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13969","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1111\/bjh.14409","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,21]]},"assertion":[{"value":"2016-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}